JPWO2021085653A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021085653A5 JPWO2021085653A5 JP2022553421A JP2022553421A JPWO2021085653A5 JP WO2021085653 A5 JPWO2021085653 A5 JP WO2021085653A5 JP 2022553421 A JP2022553421 A JP 2022553421A JP 2022553421 A JP2022553421 A JP 2022553421A JP WO2021085653 A5 JPWO2021085653 A5 JP WO2021085653A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- ring
- formula
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019199140 | 2019-10-31 | ||
| JP2019199140 | 2019-10-31 | ||
| JPPCT/JP2019/049075 | 2019-12-06 | ||
| PCT/JP2019/049075 WO2021084765A1 (en) | 2019-10-31 | 2019-12-06 | 4-aminobut-2-enamide derivatives and salts thereof |
| PCT/JP2020/041642 WO2021085653A1 (en) | 2019-10-31 | 2020-10-29 | 4-aminobut-2-enamide derivatives and salts thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023515235A JP2023515235A (ja) | 2023-04-12 |
| JPWO2021085653A5 true JPWO2021085653A5 (enExample) | 2023-11-06 |
Family
ID=73699368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022553421A Pending JP2023515235A (ja) | 2019-10-31 | 2020-10-29 | ４－アミノブタ－２－エンアミド誘導体及びその塩 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230023023A1 (enExample) |
| EP (1) | EP4051266A1 (enExample) |
| JP (1) | JP2023515235A (enExample) |
| CN (2) | CN119424423A (enExample) |
| WO (1) | WO2021085653A1 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019217307A1 (en) | 2018-05-07 | 2019-11-14 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| IL281344B2 (en) | 2018-09-10 | 2025-09-01 | Mirati Therapeutics Inc | Combination of adagrasib and cetuximab for cancer treatment |
| JP2022500385A (ja) | 2018-09-10 | 2022-01-04 | ミラティ セラピューティクス， インコーポレイテッド | 組み合わせ療法 |
| EP3849537B1 (en) | 2018-09-10 | 2024-10-23 | Mirati Therapeutics, Inc. | Combination therapies |
| CA3111980A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| JP7451419B2 (ja) | 2018-10-26 | 2024-03-18 | 大鵬薬品工業株式会社 | 新規なインダゾール化合物又はその塩 |
| CA3112129A1 (en) | 2018-12-05 | 2020-06-11 | Mirati Therapeutics, Inc. | Combination therapies |
| EP3908283A4 (en) | 2019-01-10 | 2022-10-12 | Mirati Therapeutics, Inc. | KRAS G12C INHIBITORS |
| AU2020315192A1 (en) | 2019-07-17 | 2022-02-24 | 2692372 Ontario, Inc. | Benzenesulfonamide derivatives and uses thereof |
| AU2020337938B2 (en) | 2019-08-29 | 2025-09-25 | Array Biopharma Inc. | KRas G12D inhibitors |
| MX2022003537A (es) | 2019-09-24 | 2022-07-11 | Mirati Therapeutics Inc | Terapias de combinacion. |
| CR20220230A (es) | 2019-10-28 | 2022-06-15 | Merck Sharp & Dohme | Inhibidores de pequeñas moléculas de mutante g12c de kras |
| EP4067343A4 (en) | 2019-11-29 | 2024-01-03 | Taiho Pharmaceutical Co., Ltd. | NEW PHENOLIC COMPOUND OR SALT THEREOF |
| EP4076418A4 (en) | 2019-12-20 | 2024-01-24 | Mirati Therapeutics, Inc. | Sos1 inhibitors |
| CA3183032A1 (en) | 2020-06-18 | 2021-12-23 | Mallika Singh | Methods for delaying, preventing, and treating acquired resistance to ras inhibitors |
| MX2023002248A (es) | 2020-09-03 | 2023-05-16 | Revolution Medicines Inc | Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2. |
| AU2021340716A1 (en) | 2020-09-11 | 2023-03-30 | Mirati Therapeutics, Inc. | Crystalline forms of a KRas G12C inhibitor |
| US12162893B2 (en) | 2020-09-23 | 2024-12-10 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| AU2021401232A1 (en) | 2020-12-15 | 2023-06-22 | Mirati Therapeutics, Inc. | Azaquinazoline pan-kras inhibitors |
| US11999753B2 (en) | 2020-12-16 | 2024-06-04 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-KRas inhibitors |
| WO2022133345A1 (en) | 2020-12-18 | 2022-06-23 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| EP4329749A4 (en) * | 2021-04-27 | 2025-03-19 | Merck Sharp & Dohme LLC | SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT |
| WO2024040131A1 (en) | 2022-08-17 | 2024-02-22 | Treeline Biosciences, Inc. | Pyridopyrimidine kras inhibitors |
| PE20252384A1 (es) | 2022-11-21 | 2025-10-10 | Treeline Biosciences Inc | Inhibidores espirociclicos de kras basados en dihidropiranopirimidina |
| WO2024175999A2 (en) | 2023-02-23 | 2024-08-29 | Dunad Therapeutics Ltd. | Benzenesulfonamide derivatives and uses thereof |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025064848A1 (en) | 2023-09-21 | 2025-03-27 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyridine kras inhibitors |
| TW202530228A (zh) | 2023-10-12 | 2025-08-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| TW202535891A (zh) | 2023-10-20 | 2025-09-16 | 美商默沙東有限責任公司 | Ｋｒａｓ蛋白之小分子抑制劑 |
| TW202527924A (zh) * | 2023-11-03 | 2025-07-16 | 大陸商江蘇豪森藥業集團有限公司 | 多環化合物、製備方法及其醫藥用途 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547477A (zh) * | 2024-04-01 | 2025-12-16 | 大陸商江蘇豪森藥業集團有限公司 | 大環化合物、其製備方法及醫藥用途 |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025245127A1 (en) | 2024-05-21 | 2025-11-27 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026012500A1 (en) * | 2024-07-12 | 2026-01-15 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Multi-membered macrocyclic compounds, preparation methods and medicinal uses thereof |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
| PT98990A (pt) | 1990-09-19 | 1992-08-31 | American Home Prod | Processo para a preparacao de esteres de acidos carboxilicos de rapamicina |
| US5120842A (en) | 1991-04-01 | 1992-06-09 | American Home Products Corporation | Silyl ethers of rapamycin |
| US5100883A (en) | 1991-04-08 | 1992-03-31 | American Home Products Corporation | Fluorinated esters of rapamycin |
| US5118678A (en) | 1991-04-17 | 1992-06-02 | American Home Products Corporation | Carbamates of rapamycin |
| US5118677A (en) | 1991-05-20 | 1992-06-02 | American Home Products Corporation | Amide esters of rapamycin |
| US5151413A (en) | 1991-11-06 | 1992-09-29 | American Home Products Corporation | Rapamycin acetals as immunosuppressant and antifungal agents |
| ZA935111B (en) | 1992-07-17 | 1994-02-04 | Smithkline Beecham Corp | Rapamycin derivatives |
| ZA935112B (en) | 1992-07-17 | 1994-02-08 | Smithkline Beecham Corp | Rapamycin derivatives |
| US5256790A (en) | 1992-08-13 | 1993-10-26 | American Home Products Corporation | 27-hydroxyrapamycin and derivatives thereof |
| GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
| US5258389A (en) | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
| EP0669929B1 (en) | 1992-11-13 | 2007-01-03 | Immunex Corporation | Elk ligand, a cytokine |
| US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| US5516658A (en) | 1993-08-20 | 1996-05-14 | Immunex Corporation | DNA encoding cytokines that bind the cell surface receptor hek |
| EP0729471A1 (en) | 1993-11-19 | 1996-09-04 | Abbott Laboratories | Semisynthetic analogs of rapamycin (macrolides) being immunomodulators |
| NZ277498A (en) | 1993-12-17 | 1998-03-25 | Novartis Ag | Rapamycin derivatives |
| WO1995028484A1 (en) | 1994-04-15 | 1995-10-26 | Amgen Inc. | Hek5, hek7, hek8, hek11, new eph-like receptor protein tyrosine kinases |
| US6303769B1 (en) | 1994-07-08 | 2001-10-16 | Immunex Corporation | Lerk-5 dna |
| US5919905A (en) | 1994-10-05 | 1999-07-06 | Immunex Corporation | Cytokine designated LERK-6 |
| US6057124A (en) | 1995-01-27 | 2000-05-02 | Amgen Inc. | Nucleic acids encoding ligands for HEK4 receptors |
| US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| DK0821671T3 (da) | 1995-04-20 | 2001-04-23 | Pfizer | Arylsulfonylhydroxamsyrederivater som MMP- og TNF-inhibitorer |
| KR100400620B1 (ko) | 1995-06-09 | 2004-02-18 | 노파르티스 아게 | 라파마이신유도체 |
| ES2183905T3 (es) | 1995-12-20 | 2003-04-01 | Hoffmann La Roche | Inhibidores de metaloproteasa de matriz. |
| US6258823B1 (en) | 1996-07-12 | 2001-07-10 | Ariad Pharmaceuticals, Inc. | Materials and method for treating or preventing pathogenic fungal infection |
| HUP9903014A3 (en) | 1996-07-18 | 2000-08-28 | Pfizer | Phosphinate derivatives having matrix metalloprotease inhibitor effect and medicaments containing the same |
| US6153609A (en) | 1996-08-23 | 2000-11-28 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| AU5131998A (en) | 1997-01-06 | 1998-08-03 | Pfizer Inc. | Cyclic sulfone derivatives |
| ES2202796T3 (es) | 1997-02-03 | 2004-04-01 | Pfizer Products Inc. | Derivados de acidos arilsulfonilaminohidroxamicos. |
| JP2000507975A (ja) | 1997-02-07 | 2000-06-27 | ファイザー・インク | Ｎ−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用 |
| BR9807678A (pt) | 1997-02-11 | 2000-02-15 | Pfizer | Derivados de ácidos arilsulfonil-hidroxâmicos |
| US6150395A (en) | 1997-05-30 | 2000-11-21 | The Regents Of The University Of California | Indole-3-carbinol (I3C) derivatives and methods |
| ID23668A (id) | 1997-08-08 | 2000-05-11 | Pfizer Prod Inc | Turunan asam ariloksiarilsulfonilamino hidroksamat |
| GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
| GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
| PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
| PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
| ES2213985T3 (es) | 1998-11-05 | 2004-09-01 | Pfizer Products Inc. | Derivados de hidroxiamida de acido 5-oxo-pirrolidin-2-carboxilico. |
| GB9912961D0 (en) | 1999-06-03 | 1999-08-04 | Pfizer Ltd | Metalloprotease inhibitors |
| JP4587626B2 (ja) | 1999-06-07 | 2010-11-24 | イミュネックス・コーポレーション | Ｔｅｋアンタゴニスト |
| US6521424B2 (en) | 1999-06-07 | 2003-02-18 | Immunex Corporation | Recombinant expression of Tek antagonists |
| ES2219388T3 (es) | 1999-08-24 | 2004-12-01 | Ariad Gene Therapeutics, Inc. | 28-epi-rapalogos. |
| US6727225B2 (en) | 1999-12-20 | 2004-04-27 | Immunex Corporation | TWEAK receptor |
| AU4721901A (en) | 2000-02-25 | 2001-09-03 | Immunex Corp | Integrin antagonists |
| CA2531454C (en) | 2003-07-08 | 2011-10-25 | Novartis Ag | Use of rapamycin and rapamycin derivatives for the treatment of bone loss |
| EP1648900A4 (en) | 2003-07-11 | 2010-02-10 | Ariad Pharma Inc | PHOSPHORUS MACROCYCLES |
| TW200523262A (en) | 2003-07-29 | 2005-07-16 | Smithkline Beecham Corp | Inhibitors of AKT activity |
| BRPI0513915A (pt) | 2004-08-26 | 2008-05-20 | Pfizer | compostos aminoeteroarila enantiomericamente puros como inibidores de proteìna quinase |
| TW200626610A (en) | 2004-10-13 | 2006-08-01 | Wyeth Corp | Analogs of 17-hydroxywortmannin as PI3K inhibitors |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| AU2006293620A1 (en) | 2005-09-20 | 2007-03-29 | Pfizer Products Inc. | Dosage forms and methods of treatment using a tyrosine kinase inhibitor |
| CA2699202C (en) | 2007-09-12 | 2016-09-27 | F. Hoffmann-La Roche Ag | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
| EP2214675B1 (en) | 2007-10-25 | 2013-11-20 | Genentech, Inc. | Process for making thienopyrimidine compounds |
| US8772283B2 (en) | 2011-04-06 | 2014-07-08 | Taiho Pharmaceutical Co., Ltd. | Imidazo-oxazine compound or salt thereof |
| EP2970121B1 (en) | 2013-03-15 | 2017-12-13 | Araxes Pharma LLC | Covalent inhibitors of kras g12c |
| MX2016002974A (es) | 2013-09-09 | 2016-06-02 | Peloton Therapeutics Inc | Eteres de arilo y sus usos. |
| EP3636639A1 (en) | 2013-10-10 | 2020-04-15 | Araxes Pharma LLC | Inhibitors of kras g12c |
| ES2989326T3 (es) | 2015-10-21 | 2024-11-26 | Otsuka Pharma Co Ltd | Compuestos de benzolactama como inhibidores de la proteína cinasa |
| CN107556289A (zh) * | 2017-06-22 | 2018-01-09 | 天津国际生物医药联合研究院 | 一种氯苯‑吡啶类化合物及其应用 |
| GB201715342D0 (en) * | 2017-09-22 | 2017-11-08 | Univ Nottingham | Compounds |
| WO2019099703A1 (en) * | 2017-11-16 | 2019-05-23 | Sidecar Therapeutics, Inc. | Apoptosis signal-regulating kinase 1 (ask 1) inhibitor compounds |
| JP7326305B2 (ja) | 2018-03-02 | 2023-08-15 | 大塚製薬株式会社 | 医薬化合物 |
| MX2021000795A (es) | 2018-07-24 | 2021-04-12 | Taiho Pharmaceutical Co Ltd | Compuestos heterociclicos para inhibir la actividad de shp2. |
| US20240246968A1 (en) * | 2021-04-27 | 2024-07-25 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras g12c mutant |
-
2020
- 2020-10-29 WO PCT/JP2020/041642 patent/WO2021085653A1/en not_active Ceased
- 2020-10-29 EP EP20819899.4A patent/EP4051266A1/en active Pending
- 2020-10-29 US US17/773,215 patent/US20230023023A1/en active Pending
- 2020-10-29 CN CN202411574064.2A patent/CN119424423A/zh active Pending
- 2020-10-29 JP JP2022553421A patent/JP2023515235A/ja active Pending
- 2020-10-29 CN CN202080087842.9A patent/CN115551500A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021085653A5 (enExample) | ||
| ES2391382T3 (es) | Compuestos de aril-urea en combinación con otros agentes citostáticos o citotóxicos para tratamiento de cánceres humanos | |
| ES2732230T3 (es) | Compuestos que anulan el punto de control G2 del ciclo celular para una utilización en el tratamiento del cáncer | |
| JP2025160318A5 (enExample) | ||
| JP2020125349A5 (enExample) | ||
| US12428416B2 (en) | ERK inhibitors and uses thereof | |
| JP2018502900A5 (enExample) | ||
| CN111051300B (zh) | 作为组蛋白脱乙酰基酶1和/或2(hdac1-2)的选择性抑制剂的新杂芳基酰胺衍生物 | |
| CN105163584A (zh) | 用于治疗癌症的化合物 | |
| AU2014264370A1 (en) | Novel histone deacetylase inhibitors | |
| ES2660215T3 (es) | Potenciador de efecto antitumoral que comprende un compuesto de imidazooxazina | |
| RU2000129508A (ru) | Сульфонамид-содержащие соединения индола | |
| RU2007140734A (ru) | Замещенные гетероциклы и их применение в качестве ингибиторов chki, pdki и pak | |
| JP2011510028A5 (enExample) | ||
| ES2922898T3 (es) | Inhibidores multifuncionales de las rutas biológicas de MEK/PI3K y mTOR/MEK/PI3K y métodos terapéuticos que usan los mismos | |
| JP2020097596A5 (enExample) | ||
| CA3025722A1 (en) | Combinations comprising histone deacetylase inhibitors | |
| CN108366979B (zh) | 与泛素化－蛋白酶体系统有关的化合物及医药组合物 | |
| JPWO2020260252A5 (enExample) | ||
| CA2723440A1 (en) | Sulfobetaines for therapy | |
| WO2022199627A1 (en) | Polycyclic compounds and uses thereof | |
| CA2550350A1 (en) | 2-(hetero)aryl-substituted tetrahydroquinoline derivatives | |
| WO2018043530A1 (ja) | 抗腫瘍剤、抗腫瘍効果増強剤及び抗腫瘍用キット | |
| JP2018514557A5 (enExample) | ||
| TWI638825B (zh) | 抑制癌症及病毒之化合物 |